Moxifloxacină Rompharm (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacină Rompharm, is a fluoroquinolone presented as a sterile ophthalmic preparation for ocular use. It is employed to treat bacterial infections of the eye, including conjunctivitis and keratitis, in adult patients.

GNH USA supplies Moxifloxacină Rompharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Its distribution network ensures timely delivery across Europe, Asia, Africa and the Americas.

Moxifloxacin is indicated for bacterial ocular infections, targeting common pathogens that affect the eye surface and cornea.

- Bacterial conjunctivitis: reduces bacterial load and accelerates symptom resolution in acute conjunctival infection. - Bacterial keratitis: eradicates causative organisms and promotes corneal healing in infectious keratitis. - Post‑operative ocular infection: prevents or treats bacterial contamination following eye surgery. - Corneal ulcer: facilitates healing of bacterial corneal ulcers and limits scarring.

Moxifloxacin eye drops may cause local and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Eye irritation: transient burning or stinging sensation after instillation. - Redness: mild conjunctival hyperemia. - Tearing: increased lacrimation. - Foreign body sensation: feeling of grit in the eye. - Blurred vision: temporary visual disturbance. - Photophobia: heightened sensitivity to light.

Serious or Rare Side Effects: - Corneal ulceration: worsening of corneal lesions. - Allergic reaction: eyelid edema, rash, or anaphylaxis. - Stevens‑Johnson syndrome: severe mucocutaneous eruption. - Tendon rupture: rare systemic effect, especially with systemic exposure. - Severe ocular inflammation: uveitis or keratitis exacerbation.

Before prescribing Moxifloxacin ophthalmic solution, clinicians should consider several safety precautions to minimize risks. - Allergy assessment: avoid use in patients with known hypersensitivity to fluoroquinolones or any component of the formulation. - Contact lens use: discontinue contact lenses during treatment to prevent drug absorption and irritation. - Corneal disease: use with caution in patients with pre‑existing corneal epithelial defects or severe dry eye. - Systemic exposure: monitor for systemic fluoroquinolone adverse effects in patients receiving concurrent oral or intravenous therapy. - Concomitant steroids: avoid or limit topical corticosteroids as they may mask infection progression. - Pregnancy and lactation: prescribe only if the potential benefit justifies the potential risk, as safety data are limited. - Store at ambient temperature: keep the product in its original container, protect from light and moisture, and store below 25 °C.

Moxifloxacin can interact with other ophthalmic or systemic agents, influencing its efficacy or safety.

Major Interactions (Avoid): - Systemic fluoroquinolones: concurrent use may increase risk of tendon rupture and central nervous system effects. - Cation‑containing eye drops (e.g., aluminum, calcium, magnesium): may chelate the drug and markedly reduce ocular absorption.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may suppress inflammatory signs and conceal worsening infection. - Non‑steroidal anti‑inflammatory eye drops: could increase irritation or affect healing. - Anticholinergic agents: may exacerbate dry eye, enhancing discomfort with the ophthalmic solution.